<DOC>
	<DOCNO>NCT01755156</DOCNO>
	<brief_summary>The purpose study assess safety efficacy omarigliptin compare placebo participant inadequate glycemic control metformin monotherapy . The primary hypothesis 24 week , addition treatment omarigliptin provide great reduction hemoglobin A1c ( A1C ) placebo .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Efficacy Addition Omarigliptin ( MK-3102 ) Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control Metformin Therapy ( MK-3102-024 )</brief_title>
	<detailed_description>Participants receive blinded omarigliptin match placebo omarigliptin 104 week . During first 24 week ( Phase A ) receive blind study medication . In Phase B ( subsequent 80 week ) , participant initiate glycemic rescue Phase A receive additional blind study medication : participant omarigliptin group receive placebo glimepiride participant placebo group receive glimepiride .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has type 2 diabetes mellitus Currently stable dose metformin monotherapy ( &gt; =1500 mg per day ) least 12 week prior study participation Male , female reproductive potential reproductive potential agree abstain heterosexual activity use ( partner use ) acceptable contraception prevent pregnancy study 21 day last dose study drug History type 1 diabetes mellitus history ketoacidosis Has treat antihyperglycemic agent ( AHA ) protocolrequired metformin within 12 week prior study participation omarigliptin time prior signing informed consent History hypersensitivity dipeptidyl peptidase IV ( DPP4 ) inhibitor History intolerance , hypersensitivity , contraindication metformin , glimepiride , insulin glargine Is weight loss program maintenance phase weight loss medication past 6 month undergone bariatric surgery within 12 month prior study participation Has undergone surgical procedure within 4 week study participation plan major surgery study Is likely require treatment &gt; =2 consecutive week repeat course corticosteroid ( inhale , nasal topical corticosteroid permit ) Currently treat hyperthyroidism thyroid hormone replacement therapy stable dose least 6 week Is expect undergo hormonal therapy preparation donate egg period trial , include 21 day last dose blind study medication History active liver disease ( nonalcoholic steatosis ) include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Human immunodeficiency virus ( HIV ) New worsen sign symptom coronary heart disease congestive heart failure within past 3 month , myocardial infarction , unstable angina , coronary artery bypass grafting , percutaneous transluminal coronary angioplasty , stroke , transient ischemic attack past 3 month Poorly control hypertension History malignancy &lt; =5 year prior study participation , except adequately treat basal cell squamous cell skin cancer situ cervical cancer Hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Positive urine pregnancy test Pregnant breastfeeding , expect conceive study include 21 day follow last dose blind study drug User recreational illicit drug recent history drug abuse Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking Has donate blood product phlebotomy &gt; 300 mL within 8 week study participation , intend donate blood product within project duration trial receive , anticipated receive , blood product within 12 week study participation within project duration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>